Rubella (German Measles) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Rubella virus belongs to the Matonaviridae family, which includes only one genus, Rubivirus. Rubella or German measles is a mild viral infection that affects children and non-immune young adults. It is characterized by low-grade fever, malaise, and swelling of lymph nodes, followed by a brief rash. Rubella is a self-limiting and benign infection in nonpregnant people. However, maternal rubella infection, especially during the first ten weeks of gestation, can result in miscarriage, fetal death, or severe congenital disabilities, collectively known as congenital rubella syndrome (CRS). Postnatal rubella infection is generally mild and resolves independently with a good prognosis. However, infants with congenital rubella syndrome may have a poorer prognosis, depending on the severity and number of organs affected. Infants with thrombocytopenia, hepatosplenomegaly, interstitial pneumonia, and pulmonary hypertension are at higher mortality risk. There's no specific treatment for rubella, but symptoms usually pass within 7 to 10 days.
·
The most common complication of rubella
infection in adolescents and adult women is the development of joint
inflammation and pain, affecting up to 70% of individuals.
Thelansis’s “Rubella (German Measles)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2021 To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Rubella (German Measles) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
KOLs insights
of Rubella (German Measles) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Rubella (German Measles) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment